Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells

被引:84
作者
Chisholm, K [1 ]
Bray, BJ [1 ]
Rosengren, RJ [1 ]
机构
[1] Univ Otago, Dept Pharmacol & Toxicol, Dunedin, New Zealand
关键词
catechins; cytotoxicity; epigallocartechin gallate; MDA-MB-231; cells; tamoxifen;
D O I
10.1097/00001813-200410000-00010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
High concentrations of specific catechins [epigallocatechin gallate (EGCG), epigallocatechin (EGC) and epicatechin gallate (ECG)] inhibit the proliferation of many different cancer cell lines. The aim of this work was to determine if low concentrations of catechins with and without 4-hydroxytamoxifen (4-OHT) co-treatment would cause significant cytotoxicity in estrogen receptor-positive (ERalpha(+)) and -negative (ERalpha(-)) human breast cancer cells. Therefore, MCF-7, T47D, MDA-MB-231 and HS578T cells were incubated with EGCG, EGC or ECG (5-25 muM) individually and in combination with 4-OHT for 7 days. Cell number was determined by the sulforhodamine B cell proliferation assay. As single agents, none of the catechins were cytotoxic to T47D cells, while only EGCG (20 muM) elicited cytotoxicity in MCF-7 cells. Additionally, no benefit was gained by combination treatment with 4-OHT. ERalpha(-) human breast cancer cells were more susceptible as all three catechins were significantly cytotoxic to HS578T cells at concentrations of 10 muM. In this cell line, combination with 4-OHT did not increase cytotoxicity. However, the most striking results were produced in MDA-MB-231 cells. In this cell line, EGCG (25 muM) produced a greater cytotoxic effect than 4-OHT (1 muM) and the combination of the two resulted in synergistic cytotoxicity. In conclusion, low concentrations of catechins are cytotoxic to ERalpha(-) human breast cancer cells, and the combination of EGCG and 4-OHT elicits synergistic cytotoxicity in MDA-MB-231 cells. (C) 2004 Lippincott Williams Wilkins.
引用
收藏
页码:889 / 897
页数:9
相关论文
共 39 条
  • [1] Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells
    Ahmad, N
    Feyes, DK
    Nieminen, AL
    Agarwal, R
    Mukhtar, H
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (24): : 1881 - 1886
  • [2] BRAY BJ, 2003, ROLE BLUCURONIDATION
  • [3] Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterparts
    Chen, ZP
    Schell, JB
    Ho, CT
    Chen, KY
    [J]. CANCER LETTERS, 1998, 129 (02) : 173 - 179
  • [4] TAMOXIFEN-ASSOCIATED HEPATOCELLULAR DAMAGE AND AGRANULOCYTOSIS
    CHING, CK
    SMITH, PG
    LONG, RG
    [J]. LANCET, 1992, 339 (8798) : 940 - 940
  • [5] Clarke M, 1998, LANCET, V351, P1451
  • [6] Adjuvant tamoxifen: Predictors of use, side effects, and discontinuation in older women
    Demissie, S
    Silliman, RA
    Lash, TL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) : 322 - 328
  • [7] Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells
    El Etreby, MF
    Liang, YY
    Wrenn, RW
    Schoenlein, PV
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1998, 51 (02) : 149 - 168
  • [8] Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines
    Ferlini, C
    Scambia, G
    Marone, M
    Distefano, M
    Gaggini, C
    Ferrandina, G
    Fattorossi, A
    Isola, G
    Panici, PB
    Mancuso, S
    [J]. BRITISH JOURNAL OF CANCER, 1999, 79 (02) : 257 - 263
  • [9] Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor negative cancer cell lines is mediated by the induction of apoptosis
    Ferlini, C
    Scambia, G
    Distefano, M
    Filippini, P
    Isola, G
    Riva, A
    Bombardelli, E
    Fattorossi, A
    Panici, PB
    Mancuso, S
    [J]. BRITISH JOURNAL OF CANCER, 1997, 75 (06) : 884 - 891
  • [10] Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
    Fisher, B
    Costantino, JP
    Wickerham, DL
    Redmond, CK
    Kavanah, M
    Cronin, WM
    Vogel, V
    Robidoux, A
    Dimitrov, N
    Atkins, J
    Daly, M
    Wieand, S
    Tan-Chiu, E
    Ford, L
    Wolmark, N
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) : 1371 - 1388